Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School, 317 George Street, Suite 105, New Brunswick, NJ 08502, USA.
College of Social Work, University of Utah, Goodwill Humanitarian Building, 395 South, 1500 East, Room 273, Salt Lake City 84108, USA; Center on Mindfulness and Integrative Health Intervention Development, University of Utah, 395 South, 1500 East, Room 273, Salt Lake City 84108, USA.
J Subst Abuse Treat. 2021 Aug;127:108468. doi: 10.1016/j.jsat.2021.108468. Epub 2021 May 8.
Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse. Mindfulness-Oriented Recovery Enhancement (MORE) is one of the few interventions developed and tested as an integrated treatment to simultaneously address both pain and illicit opioid use; however, this study is the first to evaluate MORE as an adjunct to MMT.
Randomized individuals in MMT (N = 30) received MORE plus methadone TAU (n = 15) or methadone TAU, only (n = 15). Participants in the MORE arm received their MMT, as usual, and attended eight, weekly, two-hour MORE groups at their MMT clinics. Participants in the TAU arm received their MMT, as usual, and group or individual counseling, as required by the clinic. TAU counseling consisted of relapse prevention, cognitive-behavioral therapy, and supportive treatment. TAU participants did not receive any mindfulness-based intervention. Participants completed assessments at baseline, post-treatment (i.e., 8-weeks post-baseline), and follow-up (i.e., 16-weeks post-baseline).
Participants in MORE evidenced significantly fewer baseline adjusted days of illicit drug use and significantly lower levels of craving through 16-week follow-up compared to TAU. Also, Participants in MORE reported significantly lower levels of pain, physical and emotional limitations, depression, and anxiety through 16-week follow-up compared to TAU. Conversely, participants in MORE reported significantly higher levels of well-being, vitality, and social functioning through 16-week follow-up compared to TAU.
MORE could be an effective adjunct to MMT, and larger trials are warranted.
慢性疼痛在接受美沙酮维持治疗(MMT)的阿片类药物使用障碍患者中高度普遍,已知是导致治疗中断和阿片类药物复发的重要因素。正念导向的康复增强(MORE)是为数不多的作为综合治疗开发和测试的干预措施之一,旨在同时解决疼痛和非法阿片类药物使用问题;然而,这项研究是首次评估 MORE 作为 MMT 的辅助治疗。
接受 MMT 的随机个体(N=30)接受 MORE 加美沙酮 TAU(n=15)或仅接受美沙酮 TAU(n=15)。MORE 组的参与者接受常规 MMT,并在 MMT 诊所参加每周两次、每次两小时的 MORE 组,共八次。TAU 组的参与者接受常规 MMT,并根据诊所的要求接受小组或个体咨询。TAU 咨询包括预防复发、认知行为疗法和支持性治疗。TAU 参与者未接受任何基于正念的干预。参与者在基线、治疗后(即基线后 8 周)和随访(即基线后 16 周)完成评估。
与 TAU 相比,MORE 组的参与者在基线调整后的非法药物使用天数明显减少,在 16 周随访时的渴求程度明显降低。此外,与 TAU 相比,MORE 组的参与者在 16 周随访时报告的疼痛、身体和情绪受限、抑郁和焦虑水平明显降低。相反,与 TAU 相比,MORE 组的参与者在 16 周随访时报告的幸福感、活力和社会功能水平明显提高。
MORE 可能是 MMT 的有效辅助治疗方法,需要进行更大规模的试验。